| | Dose | In vitro/in vivo | Cell line | Effective molecular mechanism | Molecular targets of quercetin | Ref. |
| Large B-lymphomas | 10 or 20 μM | In vitro | U937 | Arrests cell cycle in the G2/M phase, increases cyclin B protein levels, and decreases cyclin D and E and E2F1 and E2F2 levels | Cyclin B, cyclin D, and cyclin E | [77] | 50 μM | In vitro | Daudi and TMD-8 | Decreases expression of Notch1 protein | Notch1 protein | [78] | — | In vitro | Namalawa | Arrest of cells in the G2/M phase | Caspase-3 | [79] | 20 μM | In vitro | VAL, RL, and SUDHL-4 cell lines | Reduces expression of survivin and Mcl-1 and reduces restoration of the TRAIL pathway | TRAIL, Mcl-1 | [80] | 20 μM | In vitro | DLBCL | Inhibits p-STAT3 and decreases expression of Mcl-1, survivin, and Bcl-x1 genes | STAT3 protein | [81] | 50 μM | In vitro | BC1, BC3, and BCBL1 | Increases the number of G1 events; increases the inhibition of PI3K and mTOR kinase; reduces the Wnt activation pathway; decreases expression of c-FLIP, cyclin D1, c-Myc, and p65 NF-κB; reduces the release of IL-6 and IL-10; increases expression of HLA II (HLA-DR); decreases expression of HLA I | c-FLIP, cyclin D1, c-Myc, IL-6, IL-10, KSHV proteins, HLA-DR, and calreticulin | [59] | 50 mg | In vivo | — | Increases and decreases expression of the HIGD2A gene | Higd2a protein | [82] | Burkitt’s lymphoma | 2.5, 10, and 25 | In vivo | — | Inhibits primary viral antigens | Ornithine decarboxylase (ODC) | [83] | 30 μM | In vitro | Raji cell | Inhibits PI3Kδ; decreases expression of cIAP-1, cIAP-2, and anti-/proapoptotic molecules; inhibits the mTOR pathway; increases expression of the γH2A.X protein | PI3K and mTOR | [84] | 50 and 100 μM | In vitro | Raji, Akata, 2A8, Ramos, and BL-41 | Inhibits c-Myc expression and the PI3K/AKT/mTOR pathway, reduces expression of HSP-70, and stimulates autophagy | c-Myc protein, PI3K, AKT, and mTOR | [60] | Multiple myeloma | 100 and 200 μmol/L | In vitro | NCI-H929 | Inhibits CDK4 expression; downregulates p-ERK and p-AKT; activates apoptosis-related proteins caspase-3, caspase-8, caspase-9, and PARP | Caspase-3, caspase-8, caspase-9, PARP, Bcl-2, P53, P21, P27, CDK4, p-ERK, and p-AKT | [85] | 40, 80, 160, and 320 μmol/L | In vitro | U266, KM3, RPMI8226, and MM | Downregulates IQGAP1 expression and p-ERK1/2 and inhibits the MAPK pathway in MM cells | IQGAP1 protein and ERK1/2 | [86] | T-cell lymphoma | — | In vivo | — | Downregulates p-AKT, p-PDK1, p-BAD, p-GSK-3β, p-mTOR, p-IkBα, VEGF-A COX-2, iNOS, and NO level. Upregulates p-PTEN | AKT, PDK1, BAD, GSK-3β, mTOR, IkBα, VEGF-A, COX-2, iNOS, and PTEN | [87] | 300 μmol/L | In vitro | DLA | Downregulates p-AKT 1, p-PDK1, p-BAD, TNFR1, PKCα, and upregulates PTEN | AKT, PDK1, BAD, TNFR1, and PTEN | [88] |
|
|